View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 7, 2016updated 13 Jul 2022 10:15am

Sanofi Genzyme initiates Phase II/III trial of olipudase alfa to treat ASMD

French-based pharmaceutical company Sanofi's specialty care global business unit Sanofi Genzyme has dosed the first patient in the Ascend pivotal Phase II/III clinical trial of investigational therapy olipudase alfa to treat non-neurological manifestations of acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease type B (NPD B).

ASMD

French-based pharmaceutical company Sanofi’s specialty care global business unit Sanofi Genzyme has dosed the first patient in the Ascend pivotal Phase II/III clinical trial of investigational therapy olipudase alfa to treat non-neurological manifestations of acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease type B (NPD B).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Olipudase alfa is a recombinant human acid sphingomyelinase (rhASM), enzyme replacement therapy.

The multi-national, multi-centre, double-blinded, placebo-controlled Phase II/III Ascend trial is designed to determine the efficacy, safety, pharmacodynamics and pharmacokinetics profile of olipudase alfa.

Around 36 adult patients with ASMD will be enrolled in the trial and administered with olipudase alfa intravenously once every two weeks over a period of 52 weeks.

"The beginning of this pivotal trial is a critical milestone in the assessment of olipudase alfa’s potential to impact the lives of patients living with ASMD."

The trial will focus on determining the effect of olipudase alfa on spleen size, lung function and other important clinical parameters.

Villa Metabolica Mainz University Medical Centre principal investigator Eugen Mengel said: "ASMD is a rare and debilitating disease that can lead to serious medical conditions including failure of the lungs, liver or heart.

"The beginning of this pivotal trial is a critical milestone in the assessment of olipudase alfa’s potential to impact the lives of patients living with ASMD."

Olipudase alfa addresses the fundamental defect underlying the disease and supplements the defective or deficient native enzyme, resulting in the breakdown of sphingomyelin, whose accumulation is responsible for the clinical manifestation of ASMD.


Image: Niemann pick cell displayed in spleen. Photo: courtesy of W.CC via Wikipedia.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena